Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:49 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
NCT04337931 · Apexigen America, Inc. · PHASE2 · terminated · last registry update 2024-02-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business decision (not due to safety reason).” | – | Registry record, Apexigen America, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-17Results posted on the registry: Novartis Pharmaceuticals, CFZ533 (NCT04129528)
- 2024-10-08Results posted on the registry: Washington University School of Medicine, CDX-301 + CDX-1140 (NCT04536077)
- 2024-10-08Also stopped (terminated): Washington University School of Medicine, CDX-301 + CDX-1140 (NCT04536077)
- 2024-07-18Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Placebo (NCT03610516)
- 2024-07-03Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Tacrolimus - MMF - corticosteroids (NCT03781414)
- 2024-06-06Results posted on the registry: Novartis Pharmaceuticals, VAY736 + VAY736 Placebo (NCT03656562)
- 2024-05-02Results posted on the registry: Apexigen America, Inc., APX005M + Paclitaxel (NCT03165994)
- 2024-04-10Also stopped (terminated): HiberCell, Inc., odetiglucan + CDX-1140 (NCT05484011)
- 2024-02-28Also stopped (terminated): Albert Einstein College of Medicine, FLT3 Ligand (CDX-301) + anti-CD40 antibody (CDX-1140) (NCT04491084)
- 2023-12-05Results posted on the registry: Apexigen America, Inc., APX005M + Nivolumab (NCT03123783)
- 2023-11-07Results posted on the registry: Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-11-07Also stopped (terminated): Hoffmann-La Roche, Regorafenib + Atezolizumab (NCT03555149)
- 2023-09-11Also stopped (withdrawn): Nordic Society of Gynaecological Oncology - Clinical Trials Unit, APX005M (NCT05201001)
- 2023-08-18Results posted on the registry: Yale University, APX005M + Cabiralizumab (NCT03502330)
- 2023-07-17Results posted on the registry: Albert Einstein College of Medicine, FLT3 Ligand (CDX-301) + anti-CD40 antibody (CDX-1140) (NCT04491084)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision